^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

enadenotucirev (ColoAd1)

i
Other names: ColoAd1, Ad11/Ad3 chimeric group B adenovirus, oncolytic Ad11/Ad3 chimeric group B adenovirus, ColoAd-1, EnAd
Associations
Company:
Akamis Bio
Drug class:
Immunostimulant, Cell death stimulant
Related drugs:
Associations
7ms
Gut microbiome and gene expression changes during a Phase 1 trial of enadenotucirev and radiotherapy (ESTRO 2024)
Purpose/Objective: The CEDAR trial was a multi-centre phase 1 clinical trial (NCT03916510) in locally advanced rectal cancer patients which combined 25x2Gy chemoradiation with concurrent capecitabine and Enadenotucirev (EnAd), a tumourselective intravenous oncolytic adenovirus. S5230 Radiobiology - Microenvironment Interpatient microbial heterogeneity is greater than dynamic microbiome shifts through treatment in this study. Certain microbiome constituents may be associated with more favourable radiation responses. The absence of significant microbial variation during treatment suggests baseline microbiome features could be further explored as a predictive biomarker.
P1 data
|
ATG5 (Autophagy Related 5) • CDK1 (Cyclin-dependent kinase 1) • HPRT1 (Hypoxanthine Phosphoribosyltransferase 1) • DSG2 (Desmoglein 2)
|
nCounter® PanCancer Immune Profiling Panel
|
capecitabine • enadenotucirev (ColoAd1)
12ms
Toward the understanding of DSG2 and CD46 interaction with HAdV-11 fiber, a super-complex analysis. (PubMed, J Virol)
Enadenotucirev, a chimeric HAdV-11p/HAdV-3 adenovirus identified by bio-selection, is a low seroprevalence vector active against a broad range of human carcinoma cell lines...However, this information is very important, as it has a direct influence on the effectiveness of HAdV-11-based vectors. The aim of this work is to determine which of the two receptors, DSG2 and CD46, is involved in the attachment of the virus to the host, and what role they play in the early stages of infection.
Journal
|
CD46 (CD46 Molecule) • DSG2 (Desmoglein 2)
|
enadenotucirev (ColoAd1)
1year
A Phase 1 Trial of the Safety, Tolerability, and Biological Effects of Intravenous Enadenotucirev (EnAd), a Novel Oncolytic Virus, in Combination with Chemoradiotherapy in Locally Advanced Rectal Cancer (CEDAR). (PubMed, Int J Radiat Oncol Biol Phys)
CEDAR is the first trial to successfully combine an intravenous oncolytic adenovirus with radiation, demonstrating the feasibility and acceptability of this approach, and a new paradigm in radiosensitization in rectal cancer. Within this small Phase I study, EnAd demonstrated an acceptable safety profile with evidence of a higher-than-expected rate of response by mrTRG. Translation analysis of tissue, blood and microbiome for biological correlates of radiation synergy is underway.
P1 data • Journal • Combination therapy • Oncolytic virus • Metastases
|
capecitabine • enadenotucirev (ColoAd1)
over1year
CEDAR: Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer (clinicaltrials.gov)
P1, N=13, Completed, University of Oxford | Recruiting --> Completed | N=30 --> 13 | Trial completion date: Jan 2024 --> Feb 2023 | Trial primary completion date: Mar 2022 --> Feb 2023
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Oncolytic virus • Metastases
|
capecitabine • enadenotucirev (ColoAd1)
over1year
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE). (PubMed, J Immunother Cancer)
Intravenously dosed enadenotucirev plus nivolumab demonstrated manageable tolerability, an encouraging overall survival and induced immune cell infiltration and activation in patients with advanced/metastatic epithelial cancer. Studies of next-generation variants of enadenotucirev (T-SIGn vectors) designed to further re-program the tumor microenvironment by expressing immune-enhancer transgenes are ongoing.
Clinical • P1 data • Clinical Trial,Phase I • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL17A (Interleukin 17A)
|
Opdivo (nivolumab) • enadenotucirev (ColoAd1)
3years
SPICE: Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors (clinicaltrials.gov)
P1, N=51, Completed, PsiOxus Therapeutics Ltd | Active, not recruiting --> Completed | N=135 --> 51 | Trial completion date: Jun 2021 --> Oct 2021 | Trial primary completion date: Jun 2021 --> Oct 2021
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • enadenotucirev (ColoAd1)
over3years
SPICE: Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors (clinicaltrials.gov)
P1, N=135, Active, not recruiting, PsiOxus Therapeutics Ltd | Recruiting --> Active, not recruiting | Trial completion date: Mar 2022 --> Jun 2021 | Trial primary completion date: Dec 2021 --> Jun 2021
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • enadenotucirev (ColoAd1)
over3years
[VIRTUAL] T-SIGn cancer gene therapy and anti-EGFR CAR-T cells synergize in combination therapy to clear A549 lung tumor xenografts and lung metastases in NSG mice (AACR 2021)
We hypothesized that IV-deliverable T-SIGn cancer gene therapy vectors based on the oncolytic adenovirus enadenotucirev, which carry a transgene cassette encoding human immunomodulatory molecules to aid recruitment and activation of T-cells, could enhance the anti-tumor activity of human anti-EGFR CAR T cells in vivo...Since both agents were delivered systemically, this observation may reflect direct therapeutic activity at the metastatic sites. Taken together, these results indicate that combination therapy with a T-SIGn vector and CAR T cells holds great potential to be efficacious in humans with solid tumors.
Preclinical • Combination therapy • CAR T-Cell Therapy • IO biomarker
|
IFNG (Interferon, gamma) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IRF1 (Interferon Regulatory Factor 1) • SOCS1 (Suppressor Of Cytokine Signaling 1) • TNFSF10 (TNF Superfamily Member 10)
|
IRF1 expression
|
enadenotucirev (ColoAd1)
over3years
[VIRTUAL] A T-SIGn cancer gene therapy virus expressing an EpCAM-targeted bispecific T-cell activator stimulates T-cells and induces tumor cell death in patient-derived organotypic non-small cell lung cancer (NSCLC) spheroids ex vivo (AACR 2021)
Tumor-Specific Immuno-Gene (T-SIGn) cancer gene therapy vectors, which are based on the oncolytic adenovirus enadenotucirev, carry a gene cassette encoding combinations of human transgenes under control of the virus major late promoter (MLP) which restricts expression to tumor cells...Upregulation of IFNγ and Granzyme B in culture media indicated a strong activation of T-cells via expression of the bispecific T-cell activator. Cytotoxic T-cell activation also led to dose-dependent cell killing in NSCLC spheroids as shown by life/death analysis.Having established this proof of concept for functionality of T-SIGn viruses in PDOTS, ongoing studies are evaluating the immunomodulatory activities of a series of T-SIGn viruses expressing human IL-12 with or without other cytokine/chemokines.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • GZMB (Granzyme B)
|
EPCAM expression
|
enadenotucirev (ColoAd1)
over4years
Attenuation of the Hypoxia Inducible Factor Pathway after Oncolytic Adenovirus Infection Coincides with Decreased Vessel Perfusion. (PubMed, Cancers (Basel))
Using intravital microscopy, a decreased perfused vessel volume was observed in infected tumour nodules upon systemic delivery of EnAd, encoding the oxygen-independent fluorescent reporter UnaG to a tumour xenograft grown under an abdominal window chamber. We conclude that the attenuation of the HIF pathway upon adenoviral infection may contribute to anti-vascular and immunostimulatory effects in the periphery of established infection foci in vivo.
Journal
|
VEGFA (Vascular endothelial growth factor A) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
HIF1A expression
|
enadenotucirev (ColoAd1)